Transplant Complications Working Party (TCWP)
Study type:
Study number:
Type of treatment:
CAR T
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)
Short title:
CAR-T in elderly patients
Primary objective:
Incidence and the outcomes of complications in elderly patients after CAR T-cell treatment, for Non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)
Key inclusion criteria:
1. Patients aged 70 years or older at timepoint of first or second CAR-T
2. Malignancies: Non-hodgkin Lymphoma, multiple myeloma
3. Patients treated with CAR T up until Dec 2024
2. Malignancies: Non-hodgkin Lymphoma, multiple myeloma
3. Patients treated with CAR T up until Dec 2024
Country:
All EBMT member countries
Principal investigator:
Guillaume Dachy
EBMT Study coordinator:
William Boreland
Study coordinator email:
tcwp@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results